Source comparison
Best Ipamorelin Dosage Anti-Aging 2026: Protocol Comparison
The table below compares the three most common ipamorelin anti-aging protocols tested in clinical and research settings. Each approach reflects different trade-offs between IGF-1 response, injection frequency, and long-term receptor sensitivity. Conservative L
This comparison does not assign a generated winner or score.
- The table below compares the three most common ipamorelin anti-aging protocols tested in clinical and research settings. Each approach reflects different trade-offs between IGF-1 response, injection frequency, and long-term receptor sensitivity.
- Conservative Low-Dose
- 100–150mcg
- Once daily (pre-bed)
- 8–12% from baseline
- Minimal. Sustained use viable beyond 16 weeks
- Inconsistent responders; suitable for cautious initial trials or elderly subjects with low endogenous GH
- Standard Therapeutic
- 200–300mcg
- 15–22% from baseline
- Low if cycled 12 weeks on, 4 weeks off
- Optimal balance of efficacy and safety; best choice for most anti-aging research models
- High-Frequency Split
- 150mcg × 2
- Twice daily (morning, pre-bed)
- 14–20% from baseline
- Moderate. Receptor fatigue possible after 8–10 weeks
- No measurable benefit over single nocturnal dose; increases injection burden without improving outcomes
- Aggressive High-Dose
- 400–500mcg
- 18–26% from baseline
- High. Desensitisation typical within 8–12 weeks
- Marginal IGF-1 gains vs 300mcg; cortisol elevation and hunger spikes reported in 30% of subjects